Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children.

Dana KeiltyMohammad KhandwalaZhihui Amy LiuVicky PapaioannouEric Bouffet David C Hodgson Ryan Yee Sharon L Cushing Normand J LaperriereSameera AhmedDonald MabbottVijay Ramsawami Uri TaboriAnnie HuangUte Bartels Derek S Tsang

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Children treated with radiation and chemotherapy experience a high incidence of HL over time, with associations found between more severe HL and cisplatin or carboplatin dose as well as mean cochlea dose. Mean cochlea dose of ≤ 30 Gy is proposed as a goal to reduce the risk of HL; a lower threshold (20-25 Gy) may be considered in patients receiving platinum chemotherapy to reduce cumulative HL burden.

Keyphrases

locally advanced
young adults
hearing loss
risk factors
phase ii study
early onset
rectal cancer
randomized controlled trial
radiation therapy
blood brain barrier
squamous cell carcinoma
radiation induced
chemotherapy induced
clinical trial
drug induced